Compare GSK plc (GSK) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs NRG Energy Inc — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while NRG Energy Inc trades at $132.7 (market cap $29.10B). The key difference: GSK plc is far larger — about 3.5× NRG Energy Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | NRG | |
|---|---|---|
Market Cap | $101.34B | $29.10B |
Sector | Health | Utilities |
52-Week High | $61.18 | $184.03 |
52-Week Low | $36.20 | $120.65 |
Enterprise Value | $121.95B | $52.92B |
Dividend Yield | 3.49% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
NRG Energy (NRG) trades at $133.33, down 3.64% over 24 hours, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company shows strong revenue growth to $30.71 billion in 2025 but thin net margins of 0.74%, while analyst consensus remains bullish with a $190 price target. Recent news highlights upcoming Q2 2026 earnings on August 4 and strategic focus on energy demand trends.
Outlook is cautiously optimistic given analyst support and revenue momentum, but risks include high debt levels (56.42% debt-to-asset ratio in 2025) and volatile cash flows. Investment opportunity hinges on execution of growth initiatives and margin improvement, with near-term volatility expected around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
